Notably, metformin, the standard drug and AMPK activator in the treatment of T2D, has been suggested to serve as a neuroprotective agent for the prevention and treatment of PD [89,90,91,92,93]. The gene discussed is PRKAA1; the disease is type 2 diabetes mellitus.